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a b s t r a c t
Background: Infants are at greatest risk for pertussis morbidity and mortality. Maternal vaccination dur-
ing pregnancy has been shown to prevent pertussis in young infants in high- and middle-income coun-
tries. However, data on the levels of maternal pertussis antibodies and the efficiency of transplacental
transfer in low-income South Asian settings are limited.
Objective: To estimate the prevalence of maternal pertussis antibodies and the efficiency of transplacen-
tal transfer in rural southern Nepal.
Design/methods: Paired maternal-infant blood samples were collected from a subsample of participants
in a randomized, controlled trial of maternal influenza immunization (n = 291 pairs). Sera were tested
by enzyme-linked immunosorbent assays for pertussis toxin, filamentous hemagglutinin, pertactin,
and fimbriae. Maternal and infant pertussis antibody levels and transplacental transfer efficiency were
determined and potential factors associated with both were assessed.
Results: Elevated maternal antibodies to pertussis toxin, suggesting recent pertussis infection, were
rarely detected (4%, tested n = 305). However, paired maternal-cord sera were highly correlated across
all antibodies; transplacental antibody transfer ratios for pertussis toxin were 1.14 (n = 291, 95% CI
1.07–1.20); filamentous hemagglutinin 1.10 (n = 120, 95% CI: 1.01–1.20); fimbriae 2/3 1.05 (n = 120,
95% CI: 0.96–1.15) and pertactin 0.96 (n = 289, 95% CI: 0.91–1.00). Older gestational age was associated
with increased pertussis toxin and decreased fimbriae 2/3 antibody transport.
Conclusions: A low prevalence of maternal antibody to all four pertussis antigens was noted in Nepal, but
transplacental antibody transfer was efficient. No consistent demographic factors were associated with
elevated maternal antibody levels or efficiency of transplacental transfer. If an increase in infant pertussis
disease burden was detected in this population, maternal immunization could be an effective interven-
tion to prevent disease in early infancy.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Epidemic levels of pertussis have been reported recently,
mainly in high-income countries where acellular vaccines are
exclusively used [1–3]. Age groups particularly affected include
infants and adolescents [4,5]. The resurgence of infant pertussis
is of greatest concern as infants are at highest risk for severe mor-
bidity and mortality, particularly before they begin their primary
pertussis vaccination series [1,6].
Although adolescent and adult boosters [7] and ‘‘cocooning” of
infant caregivers by vaccination have been attempted, these
approaches have not effectively decreased infant pertussis burden
[1,8]. The most promising strategy that has recently been imple-
mented in several high- and middle-income countries has been
the vaccination of women during pregnancy [9–11]. This approach
boosts maternal antibodies, providing protection to both mothers
https://doi.org/10.1016/j.vaccine.2017.09.074
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and infants, through transplacental antibody transport and poten-
tial augmentation of breastmilk antibody [12–14].
While several studies have examined the level of maternal and
cord blood pertussis antibodies and the efficiency of transplacental
antibody transfer [15–27], few studies have been conducted in
low-income country settings where whole cell diphtheria-
tetanus-pertussis vaccine is exclusively used in infants and rates
of maternal and infant malnutrition and prematurity are high
[14]. Thus, we sought to determine maternal and cord blood anti-
body levels to four pertussis antigens, the efficiency of transplacen-
tal antibody transfer, and those factors that modify these levels.
2. Methods
2.1. Settings and population
The study was nested within a randomized controlled trial of
maternal influenza vaccination during pregnancy conducted
within a population of about 98,000 individuals in 9 administrative
Village Development Communities in Sarlahi District, Nepal [28–
30]. In brief, pregnancies were identified through a pregnancy
surveillance system (women 15–40 years) where field workers vis-
ited all households at 5 week intervals and performed urine preg-
nancy tests. Between April 25, 2011 and September 9, 2013, 3,693
women, between 17 and 34 weeks gestation, who consented to
participate, were enrolled and randomized to receive either influ-
enza vaccine or placebo in two consecutive cohorts. A substudy
of pertussis antibody prevalence was conducted in a convenience
sample of women and their liveborn infants from whom blood
samples were collected, starting approximately 10 months after
the main trial began. Study approval was obtained from Institu-
tional Review Boards at the Johns Hopkins Bloomberg School of
Public Health, Cincinnati Children’s Medical Center, Institute of
Medicine at Tribhuvan University, Kathmandu, and the Nepal
Health Research Council. The trial is registered at Clinicaltrials.gov
(NCT01034254).
2.2. Data collection
Baseline demographic and household data were collected at
enrollment. Household size was dichotomized at the median (4
versus > 4 people). Responses to twenty-five questions were used
to develop a household socioeconomic (SES) construct [31]. Results
were averaged and divided into SES quartiles for analysis. Once a
pregnancy was identified, women reported their literacy status
(binary), number of pregnancies, and date of last menstrual period.
For parity analysis, women were categorized as nulliparous or par-
ous. Field workers identified maternal ethnicity (Pahadi or
Madeshi).
Mothers were requested to collect between 2 and 5 cubic cen-
timeters of umbilical cord blood either in the home or at the local
delivery center as soon as the placenta was delivered. The woman
or her representative contacted the local study team and they col-
lected birth information, retrieved the cord blood samples, and
measured infant weight. For mothers who delivered in a health
facility, cord blood was collected by facility staff, who notified
the study team. Maternal blood was collected approximately 1
week post-partum in the home setting. All blood was transported
on ice to the central field-processing laboratory for centrifugation.
Sera were removed, aliquoted into cryovials and stored in liquid
nitrogen.
Gestational age was determined using date of last menstrual
period recorded during pregnancy surveillance. Those infants
who delivered at <37 weeks were categorized as preterm, but were
not excluded from the antibody study. Birthweight was obtained at
home after birth using a digital scale; those children with weights
collected >72 hours after birth were excluded from the analysis.
Infants were categorized as low birthweight if <2500 g. Small for
gestational age (SGA) was calculated using INTERGROWTH-21
sex-specific 10th percentile cut-off standards [32].
2.3. Laboratory assays
Immunoglobulin G (IgG) anti-pertussis toxin (PT), pertactin
(PRN), filamentous hemagglutinin (FHA), and fimbriae 2/3 (FIM)
enzyme-linked immunosorbent assays (ELISA) were performed at
Vanderbilt University School of Medicine according to previously
described methods [33]. ELISA units were assigned based on the
US Food and Drug Administration human reference pertussis antis-
era lot 3 for PT and FHA and lot 4 for PRN. An internal Vanderbilt
standard was used to calibrate FIM. The lower level of quantifica-
tion (LOQ) for each antigen was 10 ELISA units (EU)/mL.
2.4. Analytic dataset
Mother-infant pairs were included in the initial testing list if
both delivery cord and maternal post-partum blood samples were
collected (Supplemental Fig. 1). Samples with inadequate quantity
of sera for analysis were excluded; this resulted in some women
not having paired infant sera due to insufficient infant sera volume.
Due to sample availability and funding constraints, PT and PRN
testing were prioritized, resulting in different sample sizes for
the different pertussis antibodies. More details on the full sample
selection process may be found in Supplemental Fig. 1.
2.5. Statistical analysis
Maternal and infant antibody levels below the LOQ were
assigned one-half of the assay LOQ (5 EU/mL) and geometric mean
concentrations (GMC) and the percent below the LOQ were deter-
mined. Reverse cumulative distribution curves compared the dis-
tribution of log transformed antibody titers [34]. Differences in
maternal pertussis antibody levels by maternal, infant, and house-
hold characteristics were compared using non-parametric testing
for binary (Wilcoxon rank sum test with continuity correction)
and nominal (Kruskal-Wallis rank sum test) variables. Maternal
antibody titers that met or exceeded 94 EU/mL for PT were defined
as recently infected [35]; PT is the only antigen seen with pertussis
infection and none of the mothers had been recently immunized
with pertussis containing vaccines.
The ratio of infant to maternal pertussis antibody GMC was cal-
culated and correlated using the Spearman’s rank correlation. A
multivariable linear regression model was developed to examine
the association of the log ratio of infant to maternal pertussis anti-
body levels with infant, maternal, and household characteristics.
We did not use a specific p-value cut-off for inclusion and excluded
some covariates that were closely associated in the final model (for
example, low birth weight and SGA).
The cutoff for statistical significance in all testing was p < .05.
Statistical analyses were conducted in R version 3.3.2 (2016-10-
31) and Stata 14.2.
3. Results
305 mother and 291 infant blood samples collected between
March 1, 2012 and October 30, 2013 were analyzed (Supplemental
Fig. 1). The 305 maternal blood samples were collected from 4-38
days post-partum (median = 10 days). Average maternal age was
24 years compared to 23 years in the overall study population.
The 291 infant cord blood samples were collected from
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Table 1
Infant and mother antibody levels and transfer efficiency.
Range
n GMC GMC Transfer Ratio 95% CI % Below LOQ Min Max
PT
Infant 291 12.7 11.2–14.4 46% 5 377
Mother 305 11.1 9.9–12.5 52% 5 506
Transfer ratio 291 114% 107–120% 17% 2080%
FIM
Infant 124 10.0 8.2–12.3 66% 5 732
Mother 143 9.4 7.9–11.3 68% 5 508
Transfer ratio 120 105% 96–115% 8% 1380%
FHA
Infant 124 18.2 15.1–22.0 27% 5 359
Mother 143 16.2 13.7–19.1 32% 5 161
Transfer ratio 120 110% 101–120% 5% 660%
PRN
Infant 289 7.9 7.1–8.7 71% 5 1588
Mother 303 8.3 7.5–9.2 69% 5 663
Transfer ratio 289 96% 91–100% 10% 380%
Fig. 1. Reverse cumulative distribution curves of four pertussis antibodies for mothers and infants.
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families/facilities from day of birth through 6 days of age (median
= 0 days). Nine percent of infants were born prematurely with a
range of recorded gestational age between 30 and 54 weeks (based
on maternal report of date of last menstrual period). Infants
included in the serologic substudy study were more likely to be
higher SES, term gestation, normal birthweight, and born in non-
winter months (March – September) compared to infants in the
general study population. Further, infants with sera tested were
more likely to be born in a hospital/clinic setting than excluded
infants (72% versus 60%).
Infants had qualitatively higher antibody GMC than mothers for
antibody to all pertussis antigens tested, except PRN (Table 1 and
Fig. 1). Antibody to FHA had the highest absolute GMC (16.2,
18.2 EU/mL) in mothers and infants, respectively. In our sample,
3.9% (n = 12) of mothers had PT IgG 94 EU/mL, indicative of
recent pertussis infection.
Mothers who were not literate and/or of Madhesi ethnicity
independently had significantly higher PT and FHA antibody
GMC compared to mothers who were literate or of Pahadi ethnicity
(Table 2). In contrast, mothers who were literate had significantly
higher FIM antibody GMC compared to non-literate mothers.
Mothers who gave birth to male versus female infants had higher
PRN antibody GMC.
The placental transfer ratio was similar across antibody types
ranging from 114% (95% CI: 107–120%) for PT antibody to 96%
(95% CI: 91–100%) for PRN antibody (Table 1). Pairs with less than
100% transfer were observed for all 4 antibodies varying from 23%
of FHA antibody pairs to 14% of FIM antibody pairs (data not
shown). Maternal and infant antibody levels were correlated for
all 4 antibodies with the highest correlation for FHA (Spearman’s
rank correlation, 0.89) (Fig. 2).
In a multivariable regression model, older gestational age was
the only statistically significant variable associated with higher
PT antibody transfer (Table 3). For each week of increasing gesta-
tional age, the ratio of infant to maternal antibody had an absolute
increase of 3% (95% CI: 0–5%). In contrast, maternal to infant trans-
port of FIM antibody decreased by 7% (95% CI: 3–11%) for each
additional week of gestation. However this finding was not statis-
tically significant with the removal of one outlier. When analysis
was restricted to only pairs where at least one individual had an
antibody level above the LOQ, no statistically significant differ-
ences in transfer by infant, maternal or household factors were
seen (Supplemental Table 1). While the average transfer ratio
decreased as maternal antibody levels increased (Supplemental
Fig. 2), differences were not statistically significant for mothers
with antibody levels at or above the LOQ (data not shown).
4. Discussion
Transplacental antibody transfer to four pertussis antigens was
efficient with the highest ratio of infant to maternal titers of 1.14.
However, a sizeable minority (14–23%) of infants had lower per-
tussis antibody levels than their mothers. Studies from the 1940
s in unvaccinated mothers found low efficiency of maternal to
infant PT IgG transport with only 2–12% of newborns having higher
antibody levels than their mothers; however, these results were
not generated by ELISA methods and not directly comparable to
our results [36]. Recent studies of pertussis antibodies in unvacci-
nated mothers in various locations, including the US, Asia, and Eur-
ope, found efficient antibody transfer between mothers and infants
with the following percentages of antibody seen in the infants
when compared with the mothers: PT, 107–290%; FHA, 135–
183%; PRN, 120–173%; and FIM, 112–157% (ranges exclude pre-
term infants, when reported separately) [15–18,20,21,27,37,38].
While we also found high correlation between mothers and
infants, the transfer in our study population was on the lower
end of previously reported values, possibly due to the inclusion
of preterm infants. Transplacental transfer studies rarely publish
the proportion of pairs with antibody levels in infants below those
of their mothers, so we are unable to compare whether the 14–23%
of pairs with this transfer is comparable to other unvaccinated
populations. Recent data from a population of women vaccinated
during pregnancy in Switzerland indicate that 98% of infants were
seropositive after 2nd trimester vaccination and 86% after 3rd tri-
mester vaccination [39]. Additional studies are needed in low
Table 2
Comparison of maternal pertussis antibody geometric mean concentration (GMC) by infant, maternal and household characteristics.
PT PRN FHA FIM
n = 305 n = 303 n = 143 n = 143
n (%) GMC p-valuea,b n (%) GMC p-valuea,b n (%) GMC p-valuea,b n (%) GMC p-valuea,b
Infant Sex 0.96 0.03 0.81 0.16
Male 149 49% 10.9 148 49% 9.2 66 46% 15.8 66 46% 10.6
Female 156 51% 11.3 155 51% 7.6 77 54% 16.5 77 54% 8.5
Literacy 0.00 0.21 0.01 0.05
Literate 185 65% 9.8 183 65% 8.0 84 64% 13.6 84 64% 11.0
Non-literate 99 35% 15.0 99 35% 9.0 47 36% 23.1 47 36% 7.4
Parity 0.92 0.55 0.35 0.73
Nulliparous 124 41% 11.0 124 41% 8.7 58 41% 15.0 58 41% 9.8
Parous 180 59% 11.2 178 59% 8.0 84 59% 17.3 84 59% 9.3
Ethnicity 0.00 0.25 0.04 0.09
Pahadi 180 62% 9.5 178 62% 7.9 83 61% 14.1 83 61% 10.5
Madhesi 111 38% 14.9 111 38% 9.0 53 39% 20.6 53 39% 7.7
Socioeconomic statusc 0.20 0.64 0.13 0.47
Lowest Quartile (Q) 62 21% 15.2 62 21% 8.3 29 21% 22.0 29 21% 8.9
Bottom/middle Q 67 23% 10.8 66 23% 8.1 33 24% 19.2 33 24% 7.5
Upper/middle Q 88 30% 10.7 88 30% 9.0 43 32% 14.2 43 32% 10.2
Highest Q 74 25% 9.7 73 25% 7.7 31 23% 12.8 31 23% 10.9
Household crowding 0.86 0.39 0.78 0.12
Crowded (>4 people) 129 45% 11.3 128 45% 8.7 61 46% 16.1 61 46% 11.0
Uncrowded (4 people) 159 55% 11.3 158 55% 8.1 73 54% 16.7 73 54% 8.3
a Wilcoxon rank sum test with continuity correction.
b Bolded values indicate statistical significance (p-value < .05).
c Kruskal-Wallis rank sum test.
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resource populations to fully characterize the efficiency of
transplacental antibody transport.
The factors associated with increased antibody transport in
our multivariate models varied by the pertussis antigen. Older
gestational age was associated with higher PT antibody transport,
consistent with previous results in various populations
[17,20,40]. A biological rationale for lower transport in preterm
infants is that IgG transfer increases during gestation, leaving
infants born earlier with less opportunity for maternal transfer
[16,20,36,41]. However, recent data in both term and preterm
infants suggest that pertussis antibody transfer starts early in
the second trimester of pregnancy and increases with gestational
age [42].
The inconsistent role of pregnancy history, maternal literacy,
and number of household members on transplacental antibody
transport has been seen in other studies [18–20,22,27,39,40,43].
Lower health status and infection with HIV or malaria, which are
very low in our population, are factors also associated with lower
transplacental IgG transport in other studies [18,40]. The majority
of mothers had antibody levels below the LOQ except for FHA anti-
body, which is known to cross react with other bacterial antigens
[35]. A recent US study prior to maternal Tdap administration
Fig. 2. Association of mother and infant pertussis antibodies at birth.
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Table 3
Linear regression for transplacental transfer ratio (natural log transformed).a
PT PRN FHA FIM
Pair
characteristic
No/Mean (%)/(sd) TR eb 95% CI p-valueb No/Mean (%)/(sd) TR eb 95% CI p-valueb No/Mean (%)/(sd) TR eb 95% CI p-valueb No/Mean (%)/(sd) TR eb 95% CI p-valueb
Sex
Male 142 49% 1.17 1 [reference] 141 49% 0.98 1 [reference] 56 47% 1.14 1 [reference] 56 47% 1.12 1 [reference]
Female 149 51% 1.11 0.94 0.83–1.06 0.29 148 51% 0.94 0.94 0.86–1.04 0.21 64 53% 1.07 0.94 0.77–1.13 0.49 64 53% 0.99 0.83 0.70–0.98 0.03
Gestational Age (weeks) 39.4 2.3 1.03c 1.00–1.05 0.05 39.4 2.3 1.02 1.00–1.04 0.09 39.4 2.0 0.98 0.93–1.03 0.49 39.4 2.0 0.93 0.89–0.97 0.00
Birthweight
Normal birthweight 233 81% 1.16 232 81% 0.95 97 82% 1.10 97 82% 1.06
Low birthweight (<2500 g) 54 19% 1.02 53 19% 1.01 21 18% 1.10 21 18% 1.03
INTERGROWTH-21st SGA
AGA 185 68% 1.11 184 68% 0.93 75 65% 1.14 75 65% 1.03
SGA < 10% 89 32% 1.10 88 32% 0.98 41 35% 1.03 41 35% 1.03
Literacy
Non-literate 94 35% 1.05 1 [reference] 94 35% 0.88 1 [reference] 39 36% 1.11 1 [reference] 39 36% 1.06 1 [reference]
Literate 177 65% 1.18 1.12d 0.97–1.29 0.11 175 65% 1.00 1.12 1.00–1.25 0.04 70 64% 1.10 1.17 0.93–1.49 0.18 70 64% 1.09 1.08 0.88–1.33 0.44
Parity
Nulliparous 114 39% 1.14 1 [reference] 114 40% 0.96 1 [reference] 44 37% 0.99 1 [reference] 44 37% 1.05 1 [reference]
Parous 176 61% 1.14 1.00 0.88–1.13 0.96 174 60% 0.96 1.01 0.91–1.11 0.85 75 63% 1.17 1.20 0.98–1.47 0.08 75 63% 1.05 0.99 0.83–1.19 0.95
Ethnicity
Madhesi 107 39% 1.09 1 [reference] 107 39% 0.91 1 [reference] 45 40% 1.22 1 [reference] 45 40% 1.04 1 [reference]
Pahadi 170 61% 1.15 1.00 0.87–1.14 0.99 168 61% 1.00 1.04 0.94–1.16 0.44 68 60% 1.04 0.83 0.66–1.03 0.09 68 60% 1.10 1.08 0.89–1.32 0.43
Household number 5.0 3.2 1.01 1.00–1.03 0.15 4.9 3.5 1.00 0.98–1.01 0.47 5.0 3.6 0.98 0.96–1.01 0.23 5.0 3.6 0.98 0.95–1.00 0.04
Socioeconomic Status
Lowest quartile (Q) 61 22% 1.16 61 22% 0.98 26 23% 1.10 26 23% 1.11
Bottom/middle Q 63 23% 1.16 62 23% 0.95 27 24% 1.20 27 24% 1.08
Upper/middle Q 84 30% 1.15 84 31% 0.96 34 30% 1.07 34 30% 1.04
Highest Q 69 25% 1.05 68 25% 0.97 26 23% 1.09 26 23% 1.08
a Transfer Ratio (TR) = Natural log of infant/mother antibody ratio; full model inclusive of these variables: sex, gestational age, literacy status, parity status, ethnicity, and household number.
b Bolded values indicate statistical significance (p-value < .05).
c Interpretation: For every week increase in gestational age infant to maternal antibody ratio is increased by 3%.













found comparable levels to ours, with only a fifth of women at
delivery having PT antibody levels >5 EU/mL [22]. Approximately
4% of mothers in our study had high PT antibody levels suggesting
a recent pertussis infection, a similar prevalence to that reported in
Turkey [20]. While there is no serological correlate of immunity, PT
IgG antibody titers >94 EU/mL are considered indicative of recent
infection [35,44]. A sizeable proportion of infants had pertussis
antibody levels below our LOQ, similar to reports from the USA
prior to recommendations for the maternal immunization [22],
indicating that majority of infants in Nepal would be susceptible
to pertussis.
Our study has several limitations. One is that we were unable to
complete testing for all antibodies on all specimens due to limita-
tions on the sample quantity in some subjects. Another limitation
is that our study was a convenience sample and we collected blood
more frequently for some groups. These groups include infants that
were term, normal birthweight, and high SES, which may have
potentially biased our study towards higher transfer. However,
our findings of no significant differences in transfer by the key vari-
ables of gestation, birthweight or SES support minimal bias
induced by our study methods. We also do not have childhood per-
tussis vaccination records for women in our study. However, anti-
body levels following pertussis vaccination do not persist until
adulthood [45]. Finally, we may have had misclassification in our
gestational age estimates as they were based on recall of last men-
strual period (gestational age of 54 weeks is not biologically plau-
sible). However, we would anticipate that this method would
introduce bias towards higher gestational ages and provides a rea-
sonable estimate compared to ultrasound measurement in low-
resource settings [46].
Given the low concentration of maternal pertussis antibodies
detected in our study, vaccination of pregnant women would be
highly likely to increase maternal antibody levels and this antibody
would be transplacentally transferred to provide protection in
young infants. We note that there is no well-documented antibody
level that correlates with protection from pertussis infection or
disease [44,47]. However, it is interesting to speculate that the
use of whole cell pertussis vaccine in this setting may be beneficial
to the observed low incidence of infant pertussis. Although studies
of the epidemiology of pertussis disease among countries or differ-
ent settings are difficult to compare due to vast differences in test-
ing algorithms and laboratory methods, pertussis outbreaks have
been reported nearly exclusively from countries where acellular
pertussis vaccine have been utilized. The impact of the type of per-
tussis vaccine on carriage and transmission of B. pertussis is under
investigation using primate models [48], with evidence accumulat-
ing that acellular pertussis vaccines do not decrease transmission
Since the burden of severe disease and deaths from pertussis in
infants currently appears to be low in this population [49], main-
taining vaccination with whole cell vaccine seems to be warranted
and maternal immunization with pertussis vaccine does not
appear to be an important medical need in Nepal at this time [50].
5. Conclusion
Low pertussis antibody levels were found in mothers and their
newborn infants in Sarlahi District, Nepal. The most efficient anti-
body transferred was PT. Despite the high correlation between
mother and infant antibody levels to all four pertussis antigens
tested, approximately a fifth of infants had lower antibody levels
than their mothers. There was no consistent factor associated with
higher maternal antibody levels or more efficient antibody trans-
port from mothers to infants. If the estimated burden of pertussis
disease in infancy in Nepal were to increase, maternal immuniza-
tion should be considered.
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